Immunohistochemical study of MUC1, MUC2 and MUC5AC in colorectal carcinoma and review of literature

Kesari, Mrunal; Gaopande, Vandana L.; Joshi, Avinash R; Babanagare, Shreedhar V.; Gogate, Bageshree P.; Khadilkar, Ameya

doi:10.1007/s12664-015-0534-y

Cited by 33 publications

(47 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It is expressed in 19–76% of adenomas and is associated with increasing dysplasia along the adenoma-carcinoma sequence [14, 21]. Further, there is overexpression of MUC1 in most colorectal tumors, with expression in the range of 30–100% [22, 23]. Higher expression of MUC1 positively correlates with stage, metastasis, poor tumor differentiation, and worse long-term survival [22-25].…”

Section: Discussionmentioning

confidence: 99%

Mucins and associated glycan signatures in colon adenoma–carcinoma sequence: Prospective pathological implication(s) for early diagnosis of colon cancer

et al. 2016

View full text Add to dashboard Cite

Development of biomarkers that detect early stage resectable premalignant lesions of colon can provide critical aid in prevention of colorectal cancer. Recent evidences advocate the utility of mucin expression to predict malignant transformation of colon pre-neoplastic lesions. In this study, we investigated the combined expression of multiple mucins and mucin-associated glycans during the adenoma-carcinoma sequence of colon cancer progression. Further, we evaluated their applicability as markers for differentiating adenomas/adenocarcinomas from hyperplastic polyps. Immunohistochemical analyses performed on colon disease tissue microarrays revealed that MUC2, MUC4 expression were downregulated (p<0.0001) and MUC1, MUC5AC expression were upregulated (p=0.01) during adenoma-adenocarcinoma progression. Expression of MUC17 was downregulated in inflamed tissues compared to normal tissues, but its increased expression differentiated adenomas (p=0.0028) and adenocarcinomas (p=0.025) from inflammation. MUC1 specific glycan-Tn/STn-MUC1 showed higher expression in hyperplastic polyps (p=0.023), adenomas (p=0.042) and adenocarcinomas (p=0.0096) compared to normal. Multivariate regression analyses indicated that a combination of MUC2, MUC5AC, and MUC17 could effectively discriminate adenoma-adenocarcinoma from hyperplastic polyps. Altogether, a combined analysis of altered mucins and mucin-associated glycans is a useful approach to distinguish premalignant/malignant lesions of colon from benign polyps.

show abstract

Section: Discussionmentioning

confidence: 99%

Mucins and associated glycan signatures in colon adenoma–carcinoma sequence: Prospective pathological implication(s) for early diagnosis of colon cancer

et al. 2016

View full text Add to dashboard Cite

show abstract

“…The proof of concept of using mucin to mimic mucus is widely reported in the literature also by Hanes's group, who state that reduced mucin-binding in vitro has been shown to correlate with rapid penetration of nanoparticles through mucus (Xu et al, 2015). Mucin is a large transmembrane O-glycosylated protein composed for 75% of carbohydrate and 25% of amino acid (Kesari et al, 2015). Mucins are the most abundant macromolecules in mucus, about 20 types have been identified, and are responsible for the biochemical and biophysical properties of mucus (Kesari et al, 2015).…”

Section: Introductionmentioning

confidence: 96%

“…Mucin is a large transmembrane O-glycosylated protein composed for 75% of carbohydrate and 25% of amino acid (Kesari et al, 2015). Mucins are the most abundant macromolecules in mucus, about 20 types have been identified, and are responsible for the biochemical and biophysical properties of mucus (Kesari et al, 2015). An abnormal viscosity and excessive amount of mucus is involved in many respiratory diseases such as cystic fibrosis, asthma and pulmonary diseases (Pontremoli et al, 2015).…”

Section: Introductionmentioning

confidence: 99%

Exploring gold nanoparticles interaction with mucins: A spectroscopic-based study

Barbero

Coletti

Catalano

et al. 2018

International Journal of Pharmaceutics

View full text Add to dashboard Cite

The interaction between two mucin types (mucin from porcine stomach - PGM and mucin from bovine submaxillary glands - BSM) and gold nanoparticles (GNPs) of various size (5, 20 and 40 nm) and functionalization (with cysteamine or thioglycolic acid) was studied under physiological conditions, in order to investigate the affinity of the nanoparticles to the proteins. Different methods are employed to monitor the interactions: UV-vis and fluorescence spectroscopy, fluorescence lifetime, circular dichroism and transmission electron microscopy. These studies have shown the formation of a complex between GNPs and both PGM and BSM. This aspect could be of great importance for the use of gold nanoparticles for biomedical purposes in those diseases where qualitative and quantitative mucin anomalies play an essential role in mucus composition and rheology.

show abstract

“…MUC2 protein is present in the goblet cells of the colon epithelium (34,50). It has been reported that the IHC staining of MUC2 in goblet cells exhibits whole-cell filled or peri-nuclear staining patterns (51,52).…”

Section: Resultsmentioning

confidence: 99%

Expression of inositol-requiring enzyme 1β is downregulated in colorectal cancer

et al. 2017

View full text Add to dashboard Cite

The endoplasmic reticulum stress inositol-requiring enzyme (IRE) 1α/X-box binding protein (XBP) 1 signaling pathway is involved in the tumorigenesis of breast and prostate cancer. Mucin 2 (MUC2) protects colon tissues from the formation of tumors. In human colorectal cancer (CRC) the role of IRE1α, and its analogue, IRE1β, has yet to be elucidated. In the present study, the expression levels of IRE1α, IRE1β, un-spliced XBP1u, spliced XBP1s and MUC2 in surgically resected cancerous and adjacent non-cancerous tissues from patients with CRC were investigated. The IRE1α, IRE1β, XBP1u, XBP1s and MUC2 mRNA expression levels were determined using reverse transcription-quantitative polymerase chain reaction, and the protein expression levels were detected using immunohistochemistry and western blotting. The association between the expression levels of IRE1α, IRE1β and MUC2 and the clinicopathological features of patients with CRC was subsequently analyzed. The mRNA expression levels of IRE1β and MUC2 were decreased by ~2.1 and ~4.5-fold in CRC tissues, respectively, as compared with the adjacent normal tissues. The protein expression levels of IRE1β and MUC2 were decreased by ~8.0 and ~2.0-fold in the CRC tissues, respectively. IRE1β mRNA expression levels were positively correlated with MUC2 mRNA expression levels. IRE1β expression levels were revealed to be significantly associated with lymph node metastasis, tumor stage and histological differentiation. However, IRE1α, XBP1u and XBP1s mRNA and IRE1α protein expression levels were not observed to significantly differ between cancerous tissues and the adjacent normal tissues. The results indicated that the expression of IRE1β, but not IRE1α, may protect colon tissue from developing CRC by inducing MUC2 expression. Therefore, decreased IRE1β expression levels may be associated with the development of CRC through the inhibition of MUC2 expression.

show abstract

Immunohistochemical study of MUC1, MUC2 and MUC5AC in colorectal carcinoma and review of literature

Abstract: We do not find any correlation between tumor stage or site and MUC1, MUC2 or MUC5AC expression. MUC1and MUC5AC expression showed significant correlation with tumor grade.

Cited by 33 publications

References 17 publications

Mucins and associated glycan signatures in colon adenoma–carcinoma sequence: Prospective pathological implication(s) for early diagnosis of colon cancer

Mucins and associated glycan signatures in colon adenoma–carcinoma sequence: Prospective pathological implication(s) for early diagnosis of colon cancer

Exploring gold nanoparticles interaction with mucins: A spectroscopic-based study

Expression of inositol-requiring enzyme 1β is downregulated in colorectal cancer

Contact Info

Product

Resources

About